CADx to distribute CAD system in 14 countries
CADx Medical Systems of Montreal has signed distribution agreements for its Second Look CAD mammography system that cover 14 countries. It will be available in the U.S. when it gains FDA approval. CADx will file for FDA premarket approval after
CADx Medical Systems of Montreal has signed distribution agreements for its Second Look CAD mammography system that cover 14 countries. It will be available in the U.S. when it gains FDA approval.
CADx will file for FDA premarket approval after clinical trials, which are under way at 11 U.S. sites, are complete. The newly signed distributorships are in Australia, New Zealand, Spain, Germany, Portugal, the U.K., Ireland, Belgium, Luxembourg, France, South Korea, Poland, Singapore, and Malaysia.
After a patients mammography film has been fed into a digitizer, Second Looks software analyzes it using proprietary algorithms. Second Look produces a printed paper image, highlighting areas of potential concern. Radiologists can use the printed image to assist with a diagnosis.
R2 Technology of Los Altos, CA, markets a similar CAD system known as the ImageChecker. GE Medical Systems plans to integrate ImageChecker into its Senographe 2000D as soon as it gains FDA clearance to read soft-copy images. Senographe has approval only for hard-copy reads.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
